The B.1.1.7 lineage is a rapidly spreading variant that carries a larger than usual number of genetic changes with 10 mutations located in the spike protein
The coronavirus vaccine developed by Pfizer and BioNTech is effective against the new, more infectious coronavirus strain that was first identified in Britain, reveals analysis. The in vitro study was conducted with samples taken from people aged 18 to 85 who had been vaccinated.
When vaccinated with a dose of Pfizer vaccine, the UK coronavirus strain is neutralized, or rendered inactive by the medicine. The research team emphasizes that they found “no biologically significant difference in neutralization activity.”
The scientists created a pseudovirus with the UK Covid-19 strain’s same mutations to test against the Pfizer-BioNTech vaccine, and found that the vaccine effectively neutralized the virus pathogens for a prolonged period.
“Pfizer Inc and BioNTechSE announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech Covid-19 vaccine, BNT162b2, to neutralize the SARS-CoV-2 UK strain, also known as B.1.1.7 lineage or VOC 202012/01. Results reveal that the Covid-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-COV-2 UK strain spike protein in cell culture. Pfizer and BioNTech are encouraged by these early in vitro study findings,” write experts.
The findings are yet to be peer-reviewed and have been published online on a preprint server. The companies have also submitted the report to a peer-reviewed journal.
The B.1.1.7 lineage is a rapidly spreading variant of SARS-CoV-2 initially detected in the UK that carries a larger than the usual number of genetic changes with 10 mutations located in the spike protein. BioNTech and Pfizer have previously published data from an in vitro analysis that evaluated one of the key mutations in the UK strain, which is also shared by the South African strain.
“The previous study had also showed efficient neutralization of the N501Y mutated spike bearing virus by sera of individuals who had received the Pfizer-BioNTech Covid-19 vaccine. The current in-vitro report investigated the full set of UK strain spike mutations,” reveal authors.
Scientists, however, suggest that further data are needed to monitor the Pfizer-BioNTech coronavirus vaccine’s effectiveness in preventing Covid-19 caused by new virus variants.
“So far, for Covid-19 vaccines, it has not been established what reduction in neutralization might indicate the need for a vaccine strain change. Should a vaccine strain change be required to address virus variants in the future, the companies believe that the flexibility of BioNTech’s proprietary mRNA vaccine platform is well suited to enable such adjustment,” note researchers.
In a separate study, investigators tested plasma taken from 20 people who got two doses of either the. Brinkwire Brief News.